How volatile is RO stock?
Evaluating the stock volatility and market risk profile of Roivant Sciences Ltd.—a prominent commercial-stage biopharmaceutical enterprise focused on applying innovative technology strategies to accelerate drug development—reveals a moderate to high volatility profile characteristic of the innovative healthcare sector. Quantitative financial market analytics indicate that ROIV maintains a daily trading volatility percentage hovering around two percent alongside a beta coefficient close to zero point eight four. While the company has achieved major clinical successes, regulatory drug approvals, and substantial revenue-generating milestones, its stock valuation remains sensitive to pipeline updates, quarterly earnings reports, and broader biotechnology sector sentiment swings, requiring investors to navigate intermediate price variance.
Related FAQs
BlackRock does not own Siemens AG; it is a major institutional investor in the company. As of March 2026, BlackRock holds approximately 7.19% of Siemens' outstanding shares, representing a significant investment valued at approximately €15 billion...
Executive compensation for Thomas Schinecker in his leadership capacity as Chief Executive Officer of Roche Group reflects elite multinational healthcare industry standards. Corporate annual reports filed with Swiss regulatory authorities show tha...
Executive compensation for Blake D. Moret, serving as the Chairman and Chief Executive Officer of Rockwell Automation, Inc., reflects elite leadership within the industrial automation, digital transformation, and manufacturing technology sector. O...